More Kiran, Hanumantharaju Anil, Amrit Astha, Nimbalkar Somashekhar M, Patole Sanjay
Neonatology, MRR Children's Hospital, Thane, IND.
Neonatology, Pramukhswami Medical College, Bhaikaka University, Karamsad, IND.
Cureus. 2024 Nov 18;16(11):e73923. doi: 10.7759/cureus.73923. eCollection 2024 Nov.
Probiotics are known to reduce the risk of necrotizing enterocolitis (NEC≥ Stage II) significantly, as well as all-cause mortality, late-onset sepsis (LOS), and feeding intolerance in preterm infants. Probiotics have been reported to have comparable benefits in high- and low-middle-income countries (LMICs). We aimed to assess the current practices of neonatologists in India for using probiotics in preterm infants.
A questionnaire created using Survey Monkey's web-based tool was sent to neonatologists in India. Survey forms automatically converted responses into Excel files (Microsoft® Corp., Redmond, WA). Data were analyzed using SPSS (IBM Corp., Armonk, NY).
A total of 615 responses were received from various neonatal intensive care units (NICUs) in India (Level I: 43 (7%), II: 124 (20.8%), III: 448 (72.8%)). Around 431 (70%) of the units had either National Neonatology Forum (NNF) accreditation or IAP fellowships or were affiliated with private or government medical colleges. The remaining 184 (30%) were in private setups. Routine probiotic supplementation (RPS) was provided in 241 (39.1%) of the responding units; 179 (48%) quoted inadequate evidence as the reason for not providing RPS, 125 (33.43%) quoted difficulty in sourcing safe and effective products, whereas others were concerned about adverse effects. Most centers provided RPS for preterm infants <32 weeks and 1500 g at birth. The clinical practice was influenced by the judgment of the attending clinician. Significant variation was noticed in the protocol for RPS.
Findings of the survey suggest that approximately 39% of the participating neonatologists in India currently offer RPS for preterm infants. A significant variation exists in the selection of probiotic strains, products, dose, and duration of supplementation. Despite limitations, our findings are useful in guiding clinical practice and further research to optimize the safety and efficacy of RPS for preterm infants.
已知益生菌可显著降低坏死性小肠结肠炎(NEC≥II期)的风险,以及全因死亡率、晚发性败血症(LOS)和早产儿喂养不耐受的风险。据报道,益生菌在高收入和中低收入国家(LMICs)具有类似的益处。我们旨在评估印度新生儿科医生在早产儿中使用益生菌的当前做法。
使用Survey Monkey的基于网络的工具创建的问卷被发送给印度的新生儿科医生。调查问卷会自动将回复转换为Excel文件(微软公司,华盛顿州雷德蒙德)。使用SPSS(IBM公司,纽约州阿蒙克)对数据进行分析。
共收到来自印度各新生儿重症监护病房(NICU)的615份回复(I级:43份(7%),II级:124份(20.8%),III级:448份(72.8%))。约431个(70%)单位拥有国家新生儿学论坛(NNF)认证或印度儿科学会会员资格,或隶属于私立或政府医学院。其余184个(30%)为私立机构。241个(39.1%)回复单位提供常规益生菌补充(RPS);179个(48%)表示未提供RPS的原因是证据不足,125个(33.43%)表示难以获取安全有效的产品,而其他单位则担心不良反应。大多数中心为出生时孕周<32周且体重<1500 g的早产儿提供RPS。临床实践受主治医生判断的影响。RPS方案存在显著差异。
调查结果表明印度约39%的参与调查的新生儿科医生目前为早产儿提供RPS。在益生菌菌株、产品、剂量和补充持续时间的选择上存在显著差异。尽管存在局限性,但我们的研究结果有助于指导临床实践和进一步研究,以优化早产儿RPS的安全性和有效性。